SRC and lung carcinoma: In this analysis, eight cell lines derived from prostate cancer (PC3 and DU145), breast cancer (MDA-MB-231 and T47D), lung cancer (H1299 and H1611), and HNSCC (HN8 and HN12), were treated with two doses of the Src inhibitor saracatinib for 72 h.